0001104659-24-069787.txt : 20240607
0001104659-24-069787.hdr.sgml : 20240607
20240607192608
ACCESSION NUMBER: 0001104659-24-069787
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240607
FILED AS OF DATE: 20240607
DATE AS OF CHANGE: 20240607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GROVES JASON L
CENTRAL INDEX KEY: 0001480679
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37809
FILM NUMBER: 241031168
MAIL ADDRESS:
STREET 1: C/O MEDIFAST, INC.
STREET 2: 3600 CRONDALL LANE
CITY: OWINGS MILLS
STATE: MD
ZIP: 21117
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NeuroBo Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001638287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 472389984
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 545 CONCORD AVENUE
STREET 2: SUITE 210
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: (857) 702-9600
MAIL ADDRESS:
STREET 1: 545 CONCORD AVENUE
STREET 2: SUITE 210
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
FORMER COMPANY:
FORMER CONFORMED NAME: Gemphire Therapeutics Inc.
DATE OF NAME CHANGE: 20150331
4
1
tm2416741-5_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-06-07
0
0001638287
NeuroBo Pharmaceuticals, Inc.
NRBO
0001480679
GROVES JASON L
C/O NEUROBO PHARMACEUTICALS, INC.
545 CONCORD AVENUE, SUITE 210
CAMBRIDGE
MA
02138
1
0
0
0
0
Common Stock
2024-06-07
4
A
0
5051
0
A
17552
D
Represents a grant of restricted stock units ("RSUs") issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. Per the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier.
The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023.
/s/ Phillip D. Torrence, by Power of Attorney
2024-06-07